pembrolizumab + paclitaxel + cisplatin + carboplatin + bevacizumab

The combination of pembrolizumab, bevacizumab, and standard chemotherapy (paclitaxel with either cisplatin or carboplatin) is a multi-modal therapeutic regimen being evaluated for the treatment of recurrent, persistent, or metastatic cervical cancer. This specific combination is the subject of a Phase II investigator-initiated clinical trial (NCT02628067) led by the University of Miami. Pembrolizumab is a humanized monoclonal antibody that acts as a checkpoint inhibitor by blocking the PD-1 receptor, thereby enhancing the immune system's anti-tumor T-cell response. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. The chemotherapy backbone provides cytotoxic effects through microtubule stabilization (paclitaxel) and DNA damage (platinum agents). This combination approach aims to leverage the synergistic effects of immunotherapy, anti-angiogenesis, and cytotoxic chemotherapy in advanced cervical cancer patients.

Brand names

KeytrudaAvastin

Other names

Pembrolizumab + Chemotherapy + Bevacizumab